May 15 - 20, 2009
San Diego, USA
Data from a phase II trial with Riociguat in chronic thromboembolic pulmonary hypertension and pulmonary arterial hypertension have been presented at the American Thoracic Society (ATS) International Conference.
with
Prof. Hossein Ardeschir Ghofrani, University Hospital of Giessen and Marburg, Germany
Dr. Frank Misselwitz, Head Therapeutic Area Cardiovascular and Cardiology, Global Clinical Development
Dr. Gerrit Weimann, Therapeutic Area Cardiovascular, Global Clinical Development
Dr. Alexander Rosar, Head of Investor Relations
Background Information | |
|---|---|
About Riociguat |
|
Riociguat Clinical Trial Program |
|
About Pulmonary Hypertension |
|
To view the abstract, you first have to register on the ATS website:
After being registered you can select the abstract on Riociguat:
You are leaving the Bayer AG website.
Bayer AG is not responsible for the information on the website to which you are linking.
collect